Mobilising a global response to hepatitis: Lessons learned from the HIV movement

References

• Abdul-Quader, A. S., Feelemyer, J., Modi, S., Stein, E. S., Briceno, A., Semaan, S., … Des Jarlais, D. C. (2013). Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review. AIDS and Behavior, 17(9), 2878–2892. doi:10.1007/s10461-013-0593-y
   PubMed Web of Science ®Google Scholar
• Alter, M. J. (2007). Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology, 13(17), 2436–2441. doi: 10.3748/wjg.v13.i17.2436
   PubMed Web of Science ®Google Scholar
• Aspinall, E. J., Nambiar, D., Goldberg, D. J., Hickman, M., Weir, A., Van Velzen, E., … Hutchinson, S. J. (2014). Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: A systematic review and meta-analysis. International Journal of Epidemiology, 43(1), 235–248. doi:10.1093/ije/dyt243
   PubMed Web of Science ®Google Scholar
• Attar, B. M., & Van Thiel, D. H. (2016). Hepatitis C virus: A time for decisions. Who should be treated and when? World Journal of Gastrointestinal Pharmacology and Therapeutics, 7(1), 33–40. doi:10.4292/wjgpt.v7.i1.33
   PubMedGoogle Scholar
• Beasley, R. P. (2009). Rocks along the road to the control of HBV and HCC. Annals of Epidemiology, 19(4), 231–234. doi:10.1016/j.annepidem.2009.01.017
   PubMed Web of Science ®Google Scholar
• Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D. C., & Roudot-Thoraval, F. (2013). The burden of liver disease in Europe: A review of available epidemiological data. Journal of Hepatology, 58(3), 593–608. doi:10.1016/j.jhep.2012.12.005
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2007). Progress in hepatitis B prevention through universal infant vaccination – China, 1997–2006. MMWR Morbidity and Mortality Weekly Report, 56, 441–445.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. (2015). Hepatitis B. In J. Hamborsky, A. Kroger, & C. Wolfe (Eds.), Epidemiology and prevention of vaccine-preventable diseases (13th ed.). Washington, DC: Public Health Foundation.
   Google Scholar
• Chahal, H. S., Marseille, E. A., Tice, J. A., Pearson, S. D., Ollendorf, D. A., Fox, R. K., & Kahn, J. G. (2016). Cost-effectiveness of early treatment of Hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Internal Medicine, 176(1), 65–73. doi:10.1001/jamainternmed.2015.6011
   PubMed Web of Science ®Google Scholar
• CHRONIC HEPATITIS C TREATMENT EXPANSION: Generic Manufacturing for Developing Countries. (2015). I. GILEAD sciences. Retrieved from http://www.gilead.com/~/media/files/pdfs/other/hcvgenericagreementfactsheet.pdf?la=en
   Google Scholar
• Clements, C. J., Baoping, Y., Crouch, A., Hipgrave, D., Mansoor, O., Nelson, C. B., … Wiersma, S. (2006). Progress in the control of hepatitis B infection in the Western Pacific Region. Vaccine, 24(12), 1975–1982. doi:10.1016/j.vaccine.2005.11.035
   PubMed Web of Science ®Google Scholar
• Colvin, C. J. (2014). Evidence and AIDS activism: HIV scale-up and the contemporary politics of knowledge in global public health. Glob Public Health, 9(1–2), 57–72. doi:10.1080/17441692.2014.881519
   PubMed Web of Science ®Google Scholar
• Dutta, A., Wirtz, A. L., Baral, S., Beyrer, C., & Cleghorn, F. R. (2012). Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Current Opinion in HIV and AIDS, 7(4), 362–368. doi:10.1097/COH.0b013e328354a0b5
   PubMed Web of Science ®Google Scholar
• Elimination Manifesto. Hepatitis C Elimination in Europe: “Our vision for a Hepatitis C-free Europe”. (2016). Retrieved from http://www.hcvbrusselssummit.eu/elimination-manifesto
   Google Scholar
• El Khoury, A. C., Klimack, W. K., Wallace, C., & Razavi, H. (2012). Economic burden of hepatitis C-associated diseases in the United States. Journal of Viral Hepatitis, 19(3), 153–160. doi:10.1111/j.1365-2893.2011.01563.x
   PubMed Web of Science ®Google Scholar
• El Khoury, A. C., Wallace, C., Klimack, W. K., & Razavi, H. (2012). Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. Journal of Medical Economics, 15(5), 887–896. doi:10.3111/13696998.2012.681332
   PubMedGoogle Scholar
• Ford, N., Singh, K., Cooke, G. S., Mills, E. J., von Schoen-Angerer, T., Kamarulzaman, A., & du Cros, P. (2012). Expanding access to treatment for hepatitis C in resource-limited settings: Lessons from HIV/AIDS. Clinical Infectious Diseases, 54(10), 1465–1472. doi:10.1093/cid/cis227
   PubMed Web of Science ®Google Scholar
• Government of the People’s Republic of China. (2008). Annual Progress Report 2007, submitted to the Global Alliance for Vaccines and Immunization (GAVI) 2008. Geneva.
   Google Scholar
• Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014). Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, 61(1 Suppl.), S45–S57. doi:10.1016/j.jhep.2014.07.027
   PubMed Web of Science ®Google Scholar
• Hagan, L. M., & Schinazi, R. F. (2013). Best strategies for global HCV eradication. Liver Int, 33(Suppl. 1), 68–79. doi:10.1111/liv.12063
   PubMed Web of Science ®Google Scholar
• Hahne, S. J., Veldhuijzen, I. K., Wiessing, L., Lim, T. A., Salminen, M., & Laar, M. (2013). Infection with hepatitis B and C virus in Europe: A systematic review of prevalence and cost-effectiveness of screening. BMC Infectious Diseases, 13, 181. doi:10.1186/1471-2334-13-181
   PubMed Web of Science ®Google Scholar
• Harrington, M. (2010). From HIV to tuberculosis and back again: A tale of activism in 2 pandemics. Clinical Infectious Diseases, 50(Suppl. 3), S260–S266. doi:10.1086/651500
   PubMed Web of Science ®Google Scholar
• Hepatitis B Foundation. (2011). In A. H. A. a. I. T. C. C. (Ed.).
   Google Scholar
• Hepatitis B vaccine support. Retrieved from http://www.hepb.org/pdf/2011_Drug_Comparison.pdf
   Google Scholar
• Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014). Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical Infectious Diseases, 58(7), 928–936. doi:10.1093/cid/ciu012
   PubMed Web of Science ®Google Scholar
• Hoen, E., Berger, J., Calmy, A., & Moon, S. (2011). Driving a decade of change: HIV/AIDS, patents and access to medicines for all. Journal of the International AIDS Society, 14, 15. doi:10.1186/1758-2652-14-15
   PubMed Web of Science ®Google Scholar
• Larson, H. J., Bertozzi, S., & Piot, P. (2011). Redesigning the AIDS response for long-term impact. Bulletin of the World Health Organization, 89(11), 846–852. doi:10.2471/BLT.11.087114
   PubMed Web of Science ®Google Scholar
• Leidner, A. J., Chesson, H. W., Xu, F., Ward, J. W., Spradling, P. R., & Holmberg, S. D. (2015). Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology, 61(6), 1860–1869. doi:10.1002/hep.27736
   PubMed Web of Science ®Google Scholar
• Liang, X., Bi, S., Yang, W., Wang, L., Cui, G., Cui, F., … Wang, Y. (2009). Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. Journal of Infectious Diseases, 200(1), 39–47. doi:10.1086/599332
   PubMed Web of Science ®Google Scholar
• Lo, K.-J., Tsai, Y.-T., Lee, S.-D., Wu, T.-C., Wang, J.-Y., Chen, G.-H., … Tong, M. J. (1985). Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. Journal of Infectious Diseases, 152(4), 817–822. doi: 10.1093/infdis/152.4.817
   PubMed Web of Science ®Google Scholar
• Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., … Memish, Z. A. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet, 380(9859), 2095–2128. doi:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Medecins San Frontieres. (2015). Strategies to secure access to generic hepatitis c medicines: Overcoming patent and regulatory barriers to secure access to generic hepatitis C medicines. http://www.msfaccess.org/sites/default/files/MSF_assets/HepC/Docs/HepC_brief_OvercomingbarriersToAccess_ENG_2015.pdf
   Google Scholar
• Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013). Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology, 57(4), 1333–1342. doi:10.1002/hep.26141
   PubMed Web of Science ®Google Scholar
• Murakami, H., Van Cuong, N., Huynh, L., & Hipgrave, D. B. (2008). Implementation of and costs associated with providing a birth-dose of hepatitis B vaccine in Viet Nam. Vaccine, 26(11), 1411–1419. doi:10.1016/j.vaccine.2008.01.002
   PubMed Web of Science ®Google Scholar
• Obach, D., Deuffic-Burban, S., Esmat, G., Anwar, W. A., Dewedar, S., Canva, V., … Yazdanpanah, Y. (2014). Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: The case of Egypt. Clinical Infectious Diseases, 58(8), 1064–1071. doi:10.1093/cid/ciu066
   PubMed Web of Science ®Google Scholar
• Palmateer, N. E., Taylor, A., Goldberg, D. J., Munro, A., Aitken, C., Shepherd, S. J., … Hutchinson, S. J. (2014). Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PloS One, 9(8), e104515. doi:10.1371/journal.pone.0104515
   PubMed Web of Science ®Google Scholar
• Rabkin, M., Fouad, F. M., & El-Sadr, W. M. (2016). Addressing chronic diseases in protracted emergencies: Lessons from HIV for a new health imperative. Global Public Health, 1–7. doi:10.1080/17441692.2016.1176226
   PubMed Web of Science ®Google Scholar
• Rabkin, M., Goosby, E., & El-Sadr, W. M. (2014). Echoing the lessons of HIV: How to serve millions with cardiovascular disease. Scientific American. Retrieved from http://dx.doi.org/10.7916/D8F76C5J
   Google Scholar
• Rajagopal, D. (2015). Gilead adds ten new Countries for Sovaldi access programme. Retrieved from http://health.economictimes.indiatimes.com/news/pharma/gilead-adds-ten-new-countries-for-sovaldi-access-programme/48351057
   Google Scholar
• Ruff, T. A., Bravo, L., Gatchalian, S. R., & Bock, H. L. (2009). Priorities and challenges for hepatitis B control in the Philippines and the importance of a vaccine dose at birth. Southeast Asian Journal of Tropical Medicine and Public Health, 40(5), 972–990.
   PubMed Web of Science ®Google Scholar
• Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015). Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet, 386(10003), 1546–1555. doi:10.1016/S0140-6736(15)61412-X
   PubMed Web of Science ®Google Scholar
• Scutti, S. (2014). Will new hepatitis c guidelines from WHO help make Sovaldi and other new drugs more affordable? Retrieved from http://www.medicaldaily.com/will-new-hepatitis-c-guidelines-who-help-make-sovaldi-and-other-new-drugs-more-affordable-275594
   Google Scholar
• Sobel, H. L., Mantaring, J. B., 3rd, Cuevas, F., Ducusin, J. V., Thorley, M., Hennessey, K. A., & Nyunt, U. S. (2011). Implementing a national policy for hepatitis B birth dose vaccination in Philippines: Lessons for improved delivery. Vaccine, 29(5), 941–945. doi:10.1016/j.vaccine.2010.11.047
   PubMed Web of Science ®Google Scholar
• Tanser, F., Barnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. L. (2013). High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science, 339(6122), 966–971. doi:10.1126/science.1228160
   PubMed Web of Science ®Google Scholar
• Thomas, D. L. (2013). Global control of hepatitis C: Where challenge meets opportunity. Nature Medicine, 19(7), 850–858. doi:10.1038/nm.3184
   PubMed Web of Science ®Google Scholar
• Tu, H. A., Woerdenbag, H. J., Kane, S., Riewpaiboon, A., van Hulst, M., & Postma, M. J. (2009). Economic evaluations of hepatitis B vaccination for developing Countries. Expert Rev Vaccines, 8(7), 907–920. doi:10.1586/erv.09.53
   PubMed Web of Science ®Google Scholar
• Tucker, M. (2013). FDA approves ‘game changer’ Hepatitis C drug Sofosbuvir. Retrieved from http://www.medscape.com/viewarticle/817371
   Google Scholar
• Untangling the web of antiretroviral price reductions. (2013). http://www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions-16th-edition
   Google Scholar
• Van Damme, P., & Van Herck, K. (2007). A review of the long-term protection after hepatitis A and B vaccination. Travel Medicine and Infectious Disease, 5(2), 79–84. doi:10.1016/j.tmaid.2006.04.004
   PubMedGoogle Scholar
• Vandormael, A., Newell, M. L., Barnighausen, T., & Tanser, F. (2014). Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004–12: A prospective cohort study. Lancet Glob Health, 2(4), e209–e215. doi:10.1016/S2214-109X(14)70018-X
   PubMed Web of Science ®Google Scholar
• Venters, C., Graham, W., & Cassidy, W. (2004). Recombivax-HB: Perspectives past, present and future. Expert Review of Vaccines, 3(2), 119–129. doi:10.1586/14760584.3.4.S119
   PubMedGoogle Scholar
• Vriend, H. J., Van Veen, M. G., Prins, M., Urbanus, A. T., Boot, H. J., & Op De Coul, E. L. (2013). Hepatitis C virus prevalence in the Netherlands: Migrants account for most infections. Epidemiology and Infection, 141(6), 1310–1317. doi:10.1017/S0950268812001884
   PubMed Web of Science ®Google Scholar
• Wang, C., Wang, Y., Huang, X., Li, X., Zhang, T., Song, M., … Wang, W. (2012). Prevalence and factors associated with hepatitis B immunization and infection among men who have sex with men in Beijing, China. PloS One, 7(10), e48219. doi:10.1371/journal.pone.0048219
   PubMed Web of Science ®Google Scholar
• Wang, L., Li, J., Chen, H., Li, F., Armstrong, G. L., Nelson, C., … Shapiro, C. N. (2007). Hepatitis B vaccination of newborn infants in rural China: Evaluation of a village-based, out-of-cold-chain delivery strategy. Bulletin of the World Health Organization, 85(9), 688–694. doi: 10.2471/BLT.06.037002
   PubMed Web of Science ®Google Scholar
• WHO. (2015a). Blood safety and availability: Fact sheet N°279. Retrieved from http://www.who.int/mediacentre/factsheets/fs279/en/
   Google Scholar
• WHO. (2015b). Global immunization data. Retrieved from http://www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf?ua=1
   Google Scholar
• Wong, V. C., Ip, H. M., Reesink, H. W., Lelie, P. N., Reerink-Brongers, E. E., Yeung, C. Y., & Ma, H. K. (1984). Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet, 1(8383), 921–926. doi: 10.1016/S0140-6736(84)92388-2
   PubMed Web of Science ®Google Scholar
• Zhou, Y., Wang, H., Zheng, J., Zhu, X., Xia, W., & Hipgrave, D. B. (2009). Coverage of and influences on timely administration of hepatitis B vaccine birth dose in remote rural areas of the People’s Republic of China. American Journal of Tropical Medicine and Hygiene, 81(5), 869–874. doi:10.4269/ajtmh.2009.09-0238
   PubMed Web of Science ®Google Scholar
• Zoulim, F. (2011). Hepatitis B virus resistance to antiviral drugs: Where are we going? Liver International, 31(Suppl. 1), 111–116. doi:10.1111/j.1478-3231.2010.02399.x
   PubMed Web of Science ®Google Scholar